Clinical trials: Locally Advanced Pancreas Cancer
Pancreatic Cancer, Pancreatic Carcinoma
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were…
- Trial name
- NCT07656376
- Testing
- DN022150+AG( Stage I ）, DN022150+AG（Stage II）
- Volunteers
- 465 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Stage IV Pancreatic Cancer
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to…
- Trial name
- NCT01486329
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Vaximm GmbH
Locally Advanced or Metastatic Pancreatic Cancer
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With…
- Trial name
- NCT03579836
- Testing
- BEY1107, Gemcitabine
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- BeyondBio Inc.
Pancreatic Cancer Resectable, Pancreatic Cancer
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
This is an open-label, phase 1 clinical trial to evaluate the safety and preliminary efficacy of neoadjuvant chemoimmunotherapy (NAI, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel) followed by…
- Trial name
- ResQ108B-PANC (NCT07488884)
- Testing
- Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101)
- Sponsor
- ImmunityBio, Inc.
Pancreatic Cancer, Advanced or Metastatic
Nimotuzumab in Adults With Pancreatic Cancer
CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
- Trial name
- NCT00561990
- Testing
- Nimotuzumab
- Where
- Germany
- Volunteers
- 188 people
- Sponsor
- Oncoscience AG
Pancreatic Neoplasms
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer.
- Trial name
- LAPACT (NCT02301143)
- Testing
- nab-Paclitaxel, Gemcitabine, Chemoradiation
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Adenocarcinoma
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas.
- Trial name
- NCT01182246
- Testing
- AXP107-11
- Where
- 2 sites in Sweden
- Volunteers
- 44 people
- Sponsor
- Axcentua Pharmaceuticals AB
Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study.
- Conditions
- Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
- Trial name
- NCT06278454
- Testing
- NRT6008 Injection + Systematic chemotherapy
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Locally Advanced or Metastatic Pancreatic Cancer
Masitinib Plus Gemcitabine in Pancreatic Cancer
The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have…
- Trial name
- NCT03766295
- Testing
- Masitinib, Gemcitabine
- Where
- 9 sites in Belgium, France and 6 more
- Volunteers
- 377 people
- Sponsor
- AB Science
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Pancreas Cancer
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
- Trial name
- LAPC (NCT05191940)
- Testing
- Particle-therapy using protons or carbon ions, Blood sampling, Magnetic resonance imaging
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- EBG MedAustron GmbH
Pancreatic Adenocarcinoma
NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma.
- Trial name
- NCT01369420
- Testing
- NanoKnife Low Energy Direct Current (LEDC) System Ablation
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Angiodynamics, Inc.
Pancreatic Cancer
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable patients per cohort) will…
- Trial name
- NCT01487785
- Testing
- LDE225+gemcitabine
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals